Synlogic Inc. (SYBX)’s Financial Results Comparing With Gritstone Oncology Inc. (NASDAQ:GRTS)

As Biotechnology businesses, Synlogic Inc. (NASDAQ:SYBX) and Gritstone Oncology Inc. (NASDAQ:GRTS), are affected by contrast. This especially applies to their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Synlogic Inc. 2.52M 78.92 48.44M -2.29 0.00
Gritstone Oncology Inc. N/A 3070.20 64.81M -2.28 0.00

Table 1 highlights Synlogic Inc. and Gritstone Oncology Inc.’s gross revenue, earnings per share and valuation.


Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Synlogic Inc. -1,922.22% -39.1% -34.7%
Gritstone Oncology Inc. 0.00% 0% 0%


The Current Ratio of Synlogic Inc. is 15.2 while its Quick Ratio stands at 15.2. The Current Ratio of rival Gritstone Oncology Inc. is 6.1 and its Quick Ratio is has 6.1. Synlogic Inc. is better equipped to clear short and long-term obligations than Gritstone Oncology Inc.

Analyst Ratings

The Recommendations and Ratings for Synlogic Inc. and Gritstone Oncology Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Synlogic Inc. 0 0 0 0.00
Gritstone Oncology Inc. 0 0 2 3.00

Meanwhile, Gritstone Oncology Inc.’s consensus price target is $18.5, while its potential upside is 82.27%.

Institutional & Insider Ownership

Institutional investors owned 82.2% of Synlogic Inc. shares and 59.7% of Gritstone Oncology Inc. shares. Insiders owned 0.2% of Synlogic Inc. shares. On the other hand, insiders owned about 2.3% of Gritstone Oncology Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Synlogic Inc. -10.16% 1.73% -3.29% -14.29% -20.89% 17.26%
Gritstone Oncology Inc. 6.08% 2.27% -46.26% 0% 0% -15.28%

For the past year Synlogic Inc. has 17.26% stronger performance while Gritstone Oncology Inc. has -15.28% weaker performance.


Gritstone Oncology Inc. beats Synlogic Inc. on 6 of the 10 factors.

Synlogic, Inc. develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company is based in Cambridge, Massachusetts.

Gritstone Oncology Inc. is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.